This distinction is crucial for appropriate management and prevents unnecessary treatment modifications
The dataset connects claims, labs and EHR, including physician notes to analyse: Who meets drug label or payer criteria based on actual BMI and comorbidities How titration and dosing progress in real-world care What metabolic outcomes patients achieve over time Which safety signals, such as liver or renal changes, emerge across populations Why patients discontinue or switch treatments, as documented in notes See real-world GLP-1 evidence in action Register for our webinar where we dive deeper into GLP-1 real-world evidence
Your prescribing provider monitors your progress, tolerability, and side effects to ensure the once-weekly dose you're taking delivers the safety and efficacy you need
The researchers assessed kidney oxygenation (R2*) using blood oxygenation leveldependent MRI, and they assessed mean global kidney perfusion (GKP), renal artery resistive index (RARI), and cortical and medullary estimates of fibrosis (diffusion-weighted imaging for the apparent diffusion coefficient [ADC]) with phase-contrast MRI-measured arterial flow
2020 Mar 1;105(3):e390400